Effective January 1, 2017 - New permanent J-code for ONIVYDE®: J9205, injection, irinotecan liposome, 1 mg This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice.

FOR US HEALTHCARE PROFESSIONALS ONLY Call Us at (844) 441-6225

THE
EVIDENCE TO
FIGHT ON with ONIVYDE®

The first and only FDA-approved treatment, in combination with 5-FU/LV, for metastatic pancreatic cancer after gemcitabine-based therapy, proven to extend overall survival1

SEE THE EVIDENCE
 

FDA-APPROVED FOR
METASTATIC PANCREATIC CANCER AFTER GEMCITABINE, IN COMBINATION WITH 5-FU/LV1

Most patients in the phase 3 NAPOLI-1 trial received ONIVYDE® + 5-FU/LV in first- and second-line metastatic pancreatic cancer after gemcitabine-based therapy1,2

VIEW DETAILS

CATEGORY 1 NCCN CHEMOTHERAPY RECOMMENDATION3*

Liposomal irinotecan (ONIVYDE®) is the only Category 1 NCCN chemotherapy recommendation in post-gemcitabine metastatic pancreatic cancer3

*Liposomal irinotecan + 5-FU/LV is the only Category 1 National Comprehensive Cancer Network® (NCCN®) chemotherapy recommendation for patients with post-gemcitabine metastatic pancreatic cancer with good performance status and disease progression. Good performance status is defined as ECOG 0-1 with patent biliary stent and adequate nutritional intake.3 See the NCCN Guidelines for Pancreatic Adenocarcinoma for a complete list of recommended treatment options. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

REVIEW NOW

LIPOSOMAL ENCAPSULATION1

ONIVYDE® is encapsulated in a liposome with prolonged circulation1

LEARN MORE

SAFETY PROFILE STUDIED IN A LARGE PHASE 3 TRIAL1

The safety profile of ONIVYDE® + 5-FU/LV was well-characterized in NAPOLI-1, the largest phase 3 trial in patients with metastatic pancreatic cancer with disease progression after gemcitabine-based therapy1,2,4

SEE CLINICAL RESULTS

IPSEN CARES®

Tap into helpful resources on coverage, access, and reimbursement for patients and caregivers

GET HELP

5-FU=fluorouracil; ECOG=Eastern Cooperative Oncology Group; LV=leucovorin.

INDICATION AND IMPORTANT SAFETY INFORMATION

**National Comprehensive Cancer Network® (NCCN®).

References: 1. ONIVYDE® [package insert]. Basking Ridge, NJ. Ipsen Biopharmaceuticals, Inc.; 2017. 2. Wang-Gillam A, Li C-P, Bodoky G, et al. Lancet. 2016;387:545-557. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pancreatic Adenocarcinoma V.3.2017. ©National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed November 2, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 4. Data on file #1. Basking Ridge, NJ. Ipsen Biopharmaceuticals, Inc.; 2015.

EXPAND

INDICATION AND IMPORTANT
SAFETY INFORMATION